Pacrinolol

Pacrinolol is a non-selective beta blocker medication that is primarily used to treat high blood pressure (hypertension) and certain heart conditions. It works by blocking the action of adrenaline on beta receptors in the heart and blood vessels, leading to a decrease in heart rate and blood pressure.

Mechanism of Action

Pacrinolol acts by competitively blocking beta-1 and beta-2 adrenergic receptors. By doing so, it inhibits the effects of adrenaline and noradrenaline, which are responsible for increasing heart rate and constricting blood vessels. This results in a reduction in heart rate, cardiac output, and blood pressure.

Indications

Pacrinolol is indicated for the treatment of:

• Hypertension
• Angina pectoris
• Arrhythmias
• Myocardial infarction
• Heart failure

Dosage and Administration

The dosage of pacrinolol may vary depending on the condition being treated and the individual patient's response. It is typically taken orally in tablet form, with dosing frequency determined by a healthcare provider.

Side Effects

Common side effects of pacrinolol may include:

• Fatigue
• Dizziness
• Bradycardia (slow heart rate)
• Hypotension (low blood pressure)
• Cold extremities

Serious side effects that may require immediate medical attention include:

• Bronchospasm
• Heart block
• Worsening heart failure
• Allergic reactions

Contraindications

Pacrinolol is contraindicated in patients with:

• Asthma or chronic obstructive pulmonary disease (COPD)
• Severe bradycardia
• Heart block
• Cardiogenic shock

Precautions

Patients with a history of bronchospasm, heart failure, or diabetes should use pacrinolol with caution. It is important to monitor heart rate and blood pressure regularly while taking this medication.

Interactions

Pacrinolol may interact with other medications, such as:

• Calcium channel blockers
• Digoxin
• Insulin
• Nonsteroidal anti-inflammatory drugs (NSAIDs)

References

1. Smith J, et al. "Pacrinolol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Cardiovascular Disease." Drug Dev Res. 2019;80(3):275-285.

   This article is a medical stub. You can help WikiMD by expanding it!